Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,617 INR | +1.05% | +0.32% | +22.21% |
Mar. 25 | Lupin to Transfer Trade Generics Business to Subsidiary Lupin Life Sciences | MT |
Mar. 18 | Indian Equities Start Week in Black, Aided by Major Auto and Metal Firms | MT |
Sales 2024 * | 199B 2.39B | Sales 2025 * | 217B 2.6B | Capitalization | 737B 8.85B |
---|---|---|---|---|---|
Net income 2024 * | 19.79B 238M | Net income 2025 * | 23.06B 277M | EV / Sales 2024 * | 3.83 x |
Net Debt 2024 * | 25.18B 302M | Net Debt 2025 * | 10B 120M | EV / Sales 2025 * | 3.45 x |
P/E ratio 2024 * |
37.3
x | P/E ratio 2025 * |
32
x | Employees | 20,933 |
Yield 2024 * |
0.44% | Yield 2025 * |
0.52% | Free-Float | 52.83% |
Latest transcript on Lupin Limited
1 day | +1.05% | ||
1 week | +0.32% | ||
Current month | -0.26% | ||
1 month | +0.03% | ||
3 months | +20.66% | ||
6 months | +42.69% | ||
Current year | +22.21% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 56 | 96-12-31 | |
Johnny Mikell
PSD | President | - | - |
Director of Finance/CFO | 59 | 07-08-12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 15-10-26 | |
Mark McDade
BRD | Director/Board Member | 69 | 21-01-27 |
Director/Board Member | 50 | 95-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1,617 | +1.05% | 865,183 |
24-03-27 | 1,600 | -0.93% | 558,090 |
24-03-26 | 1,615 | +0.41% | 939,256 |
24-03-22 | 1,608 | -0.21% | 566,433 |
24-03-21 | 1,612 | +3.12% | 1,219,742 |
Delayed Quote NSE India S.E., March 28, 2024 at 08:02 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |
- Stock
- Equities
- Stock Lupin Limited
- Stock Lupin Limited - NSE India S.E.